InvestorsHub Logo
Followers 1321
Posts 247256
Boards Moderated 52
Alias Born 12/07/2009

Re: None

Thursday, 01/20/2022 3:23:52 PM

Thursday, January 20, 2022 3:23:52 PM

Post# of 13741
From the PR: "The final medical and scientific data on Escozine has been submitted to the office of the DR Minister of Public Health Daniel Rivera, and the DR Vice-Minister of Public Health Eladio Perez Antonio. Since then, the Company also had a video conference with Mr. Rivera and members of the DR MoH, where Dr. Mikaelian and Medolife Chief Scientific Officer Dr. Khalid Matalka presented the data on Escozine. A video conference was suggested by MoH due to the high rate of Omicron cases registered in their administration. During the conference, Dr. Matalka demonstrated Escozine’s mechanism of action as a calcium (Ca2+) ion channel inhibitor, which prevents the SARS-CoV-2 virus from entering the host cell, meaning Escozine can be an effective therapy against variants of the virus. Upon the completion of the data review, the DR MoH will decide whether to approve Escozine as a COVID-19 treatment, or to simply include it in the treatment protocol against COVID-19 using its existing registration in the DR as a cancer treatment." $QNTA



ALL comments are In My Own OPINION. Please Use Your Own DD for Stock Trading.

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.